Rockville, MD, United States
Rockville, MD, United States

Time filter

Source Type

Patent
NeuralStem | Date: 2013-01-17

Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.


Patent
NeuralStem | Date: 2012-10-23

A cell line and an assay for discovering neurogenic drugs are described. The assay allows for systematic screening of test agents such as libraries of compounds.


The present invention provides methods and compositions for treating spinal cord diseases and injuires. The methods involve transplanting neural stem cells which have been previously expanded in vitro into a patient such that the cells can ameliorate the disease or injury. The stem cells to be transplanted are derived from spinal cord tissue.


Patent
The Regents Of The University Of California and NeuralStem | Date: 2015-11-30

The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.


Patent
NeuralStem | Date: 2015-12-09

The invention describes an improved synthesis for piperazine derivatized with nicotinic acid and a benzyl moiety. The product compounds are useful for treatment of neurological conditions.


A method of treating neurodegenerative conditions is provided. Neural stem cells may be implanted at and/or remote from a region of neuron degeneration. The methods can include isolating neural stem cells from regions where specific types of neurons corresponding to the neurons to be replaced are generated. The methods can include isolating neural stem cells secreting growth factors affecting the growth and/or regeneration of specific types of neuron. In this invention, we disclose a method of treating such disorders, including several neurodegenerative disorders arising from the lack of cells that produce particular neurotransmitters in neural circuitry by transplanting exogenously cultured and expanded neural progenitors which, upon transplantation into a neural tissue, differentiate into neurons capable of integrating and producing neurotransmitters in sufficient quantities and in a sufficient manner to overcome the symptoms associated with the neurodegeneration.


Patent
NeuralStem | Date: 2014-01-31

Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.


The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS.


Patent
NeuralStem | Date: 2015-06-15

Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day-130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.


Patent
Regents Of The University Of California and NeuralStem | Date: 2013-05-09

The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.

Loading NeuralStem collaborators
Loading NeuralStem collaborators